CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
metformin +1 moredrug
Likely dose
metformin 850 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01804049
NCT01804049Phase 2Completed
CompareCT.gov

Metformin and Muscle in Insulin-resistant Older Veterans

VA Office of Research and Development·interventional·Posted Mar 5, 2013·Updated Feb 11, 2020

In Brief

A Phase 2 clinical trial evaluating metformin and placebo for Prediabetes. Completed, enrolled 120 participants across 1 site.

Detailed Summary

Sarcopenia is the loss of muscle mass, strength and function with aging and is associated with increased disability, falls and fractures. Older adults with diabetes and prediabetes are insulin resistant and have a higher risk of developing sarcopenia. This study examines the use of metformin, an antidiabetic drug, for preventing the development of sarcopenia in older adults with prediabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrediabetes
CountriesUnited States
CollaboratorsOregon Health and Science University

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 5, 2013
Enrollment StartApr 8, 2014
Primary CompletionAug 31, 2018
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 13.3 years ago

Interventions

metformindrug

Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.

placebodrug

One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.